Revenue plunges, stock takes a drubbing, but Teva CEO Kåre Schultz still grabs $32.5M in chart-topping compensation

Teva’s newly filed proxy shows that Schultz’s $20 million cash bonus dropped in his first full year managing the troubled giant, pushing his total compensation package for the year to $32.5 million. That follows $16.2 million in stock awards and options that hit the year before, when Schultz earned $17 million for his compensation package. And at $49.5 million for 14 months of work, that is the top of the curve.